|Bid||36.79 x 800|
|Ask||36.89 x 1800|
|Day's Range||36.44 - 37.15|
|52 Week Range||20.02 - 50.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.89|
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena ...
Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.
- Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH) - Completed Enrollment for Olorinab Study for Pain Associated with Crohn's Disease; Data in Q3:18 - Submitted ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern ...
Arena Pharmaceuticals (NASDAQ: ARNA ) announces its next round of earnings Monday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement. Earnings and Revenue Based on Arena ...
SAN DIEGO , July 30, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its second quarter 2018 financial results and provide a corporate update ...
With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.
On Wednesday, July 11, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), ArQule Inc. (NASDAQ: ARQL), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Atara Biotherapeutics Inc. (NASDAQ: ATRA).
SAN DIEGO, July 10, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T. Gallahue as a non-executive director. Mr. Gallahue is a highly accomplished executive with over 25 years of leadership experience in publicly-traded life sciences companies. "We are thrilled to have Kieran join our board of directors," said Tina Nova, Chairman of the Board of Directors of Arena.
NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Major U.S. markets finished higher on Friday, but finished the week lower due to ongoing global trade concerns. The Dow Jones Industrial Average increased 0.23 ...
Top-notch Great Point Partners is investing up to $25 million in Orgenesis' (ORGS) manufacturing subsidiary to enable global expansion. Company is already generating growing revenue, and this specialist healthcare fund investment substantiates the ORGS growth opportunity. Demand for CDMOs, like ORGS, is growing as more cell therapies (like gene therapies and CAR-T cells) come to market in the coming years.
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Arena Pharmaceuticals Inc (NASDAQ:ARNA), with a market cap of US$2.44B, often getRead More...
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
My big worry about this market isn't that it is going to suddenly plunge but that it may go dead and not do much for a while. The very sedate reaction to the G-7 meeting and the Trump-Kim summit suggests that market players are not inclined to produce much volatility.
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, NY / ACCESSWIRE / June 1, 2018 / U.S. markets closed sharply lower on Thursday as the U.S. decided to impose tariffs on steel and aluminum imports from Canada, Mexico and the European Union. ...
SAN DIEGO, May 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), will be presented at the American Thoracic Society (ATS) International Conference on May 23. Dr. Hap Farber, Professor of Medicine and Director, Pulmonary Hypertension Center, Boston University/Boston Medical Center, will present an analysis of the correlation between ralinepag plasma levels and improvements in functional and hemodynamic parameters in patients with pulmonary arterial hypertension (PAH). Arena previously announced topline Phase 2 results for ralinepag in PAH in which the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in pulmonary vascular resistance compared to placebo. Ralinepag also demonstrated numerical improvement in 6-minute walk distance relative to placebo in patients on PAH specific background therapy.
Momentum has slowed after the big move on Thursday but breadth is strong at around 4300 gainers to 2500 decliners, and the number of stocks at new 12-month highs is over 250. Overall it is still a positive day but the action is sloppy and there is risk of more profit taking into the close.
A live audio webcast of the presentations will be available under the investor relations section of Arena's website at www.arenapharm.com. Arena Pharmaceuticals is focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility.
The market is doing a nice job of being unpredictable with a sudden intraday spike on no obvious news. Strength in oil is receiving most of the credit for the overall market strength today but it is likely that there are some buy programs triggered now that the S&P500 has moved over the 50-day moving average at 2672 and has held. Bears were looking for the maket to stall out as it hit the top of the recent trading range that goes back to March 22, but they are now being squeezed as the market shrugs off the Iran news and doesn't seem to need any obvious positive news catalyst to keep on running.
Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.